Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 19
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Bicara Therapeutics Inc
BCAX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$17.47
0.69
4.11%
Ult. Agg.: Oct 19, 4:38 PM
$17.47
0.69
4.11%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Bicara Therapeutics Financials
Bicara Therapeutics (BCAX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings
Avi Kapoor
PRO
Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.84) by 2.38 percent. This is a 64 percent decrease over losses of $(0.50) per share from
Benzinga Newsdesk
PRO
Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.68) by 36.76 percent. This is a 36.76 percent decrease over losses of $(0.68) per share
Benzinga Newsdesk
Earnings Scheduled For May 11, 2026
Benzinga Insights
PRO
Bicara Therapeutics Q4 EPS $(0.68), Inline
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 74.36 percent decrease over losses of $(0.39) per share from the same period last year.
Benzinga Newsdesk
Earnings Scheduled For March 30, 2026
Benzinga Insights
